GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer treatment. Its stock price is highly volatile, driven by news of clinical trials and FDA decisions regarding its innovative cell therapies.
Share prices of companies in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics (IOVA) is a biotech company developing innovative cancer treatments using tumor-infiltrating lymphocyte (TIL)-based therapies. We classify it as "Immuno-oncology." The chart below shows the general trends in this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
Iovance Biotherapeutics is a biotech company developing innovative tumor-infiltrating lymphocyte (TIL)-based immunotherapy for the treatment of solid tumors. As a component of the GURU.Markets index, it is at the forefront of oncology. The chart below represents the entire market. Evaluate how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IOVA - Daily change in the company's share price Iovance Biotherapeutics
Shares of Iovance, a biotech company specializing in cancer cell therapy, are extremely volatile. Change_co measures the market's reaction to clinical trial data and FDA decisions. This metric is an essential component in building valuation models for companies at the forefront of oncology on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Iovance Biotherapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IOVA, a pioneer in cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Iovance is a biopharmaceutical company pioneering the development of tumor-infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this field, helping to assess the risks and performance of Iovance stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Iovance Biotherapeutics
Iovance is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics, Inc. is a leader in developing innovative cancer immunotherapy using tumor-infiltrating lymphocytes (TILs). Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the enormous potential of its unique technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Iovance is a late-stage biotech whose fate hinges on the approval and success of its immunotherapy drugs. Its stock price is completely disconnected from economic cycles. Its chart is a history of binary events: positive regulatory news can trigger a surge, while failure can lead to a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Iovance Biotherapeutics
The value of Iovance, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the commercial launch of its innovative cell therapy for melanoma and the progress of clinical trials to expand its use.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is developing tumor-infiltrating lymphocyte (TIL)-based therapy—a personalized approach to cancer treatment. The company's market capitalization reflects expectations for a breakthrough in oncology. The chart below reflects the overall sentiment in the immuno-oncology sector, where Iovance is a significant player.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Iovance Biotherapeutics develops innovative cell-based cancer treatments. The company's value is derived from its scientific developments. Its stock price is entirely dependent on clinical trial results and regulatory decisions, demonstrating extreme volatility unrelated to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Iovance Biotherapeutics
For Iovance, a biotech company developing cell therapy for cancer, the weekly performance reflects expectations for a breakthrough. Any news about clinical trials, particularly in melanoma, as well as FDA decisions, could trigger explosive stock price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Iovance and the entire cell therapy sector are riding a wave of scientific breakthroughs and investor expectations. Regulatory news and clinical trial data are creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Iovance often live in their own world, isolated from broader market fluctuations. Their stock price is determined by FDA news, not inflation reports. The chart will show how often their stock moves against the broader market tide.
Market capitalization of the company, segment and market as a whole
IOVA - Market capitalization of the company Iovance Biotherapeutics
Iovance Biotherapeutics' market cap is the financial valuation of a pioneer in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. The chart reflects the long road to FDA approval and investor hopes for this personalized form of cell therapy. Its dynamics tell the story of scientific breakthroughs in the fight against cancer.
IOVA - Share of the company's market capitalization Iovance Biotherapeutics within the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a pioneer in developing tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors. Its market share in the biotech sector is based on this breakthrough approach. The chart shows how the market assesses its chances of commercializing this personalized cell therapy.
Market capitalization of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a leader in developing cell-based therapies (TILs) for the treatment of solid tumors. The chart below shows the overall market capitalization of the immuno-oncology sector. Its dynamics reflect hopes for a revolution in cancer treatment. Iovance is at the forefront of this scientific wave.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer immunotherapy, as seen in the chart, is exploring new approaches. Iovance Biotherapeutics is developing a therapy based on tumor-infiltrating lymphocytes (TILs). Its capitalization represents a risky bet on this complex but potentially highly effective technology for the treatment of solid tumors.
Book value capitalization of the company, segment and market as a whole
IOVA - Book value capitalization of the company Iovance Biotherapeutics
Iovance's schedule represents capital for cancer cell therapy. The company's R&D-stage book value consists of financial reserves and manufacturing facilities under construction. These assets are aimed at commercializing an innovative treatment method using a patient's own immune cells.
IOVA - Share of the company's book capitalization Iovance Biotherapeutics within the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is building the future of cancer cell therapy. Its stake in the sector is invested in the construction of state-of-the-art manufacturing facilities for the creation of customized tumor-infiltrating lymphocytes. This is the physical foundation for personalized medicine.
Market segment balance sheet capitalization - Oncology immuno-therapy
Iovance Biotherapeutics is a pioneer in cancer cell therapy. Pharmaceuticals, as the chart shows, are capital-intensive. Iovance is a prime example. Its business requires building its own highly complex and expensive factories to produce personalized drugs.
Book value of all companies included in the broad market index - GURU.Markets
Iovance Biotherapeutics is a biotechnology company pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer treatment. Its book value comes from its manufacturing capacity for this complex cell therapy and the capital for its commercialization.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company. Its entire market capitalization is a premium to its cash flow. This premium is a bet that its innovative cell therapy for melanoma will be commercially successful.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer therapies using a patient's own immune cells (TIL therapy). The chart shows the significant premium the market places on its cutting-edge scientific platform and the potential to transform cancer treatment.
Market to book capitalization ratio for the market as a whole
Iovance Biotherapeutics is a biotech pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer. Compared to average market valuations, as shown in this chart, its high premium is based on the revolutionary potential of its personalized approach to immunotherapy.
Debts of the company, segment and market as a whole
IOVA - Company debts Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company developing innovative cell therapies for cancer treatment. Developing and conducting clinical trials of such complex treatments requires enormous financial resources. This chart shows how the company raises capital to fund its cutting-edge, yet very expensive, research and development.
Market segment debts - Oncology immuno-therapy
Iovance Biotherapeutics is a late-stage biotech company specializing in the development of cell therapies for cancer. Preparing for commercialization of its first product requires significant investments in manufacturing and marketing. This chart shows how the company is funding this critical transition from R&D to sales.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Iovance Biotherapeutics
Iovance Biotherapeutics develops cell-based cancer treatments. This chart shows the financial structure of a research-stage biotech company. For a company with no commercial revenue, raising debt is extremely risky. Financing must be primarily through equity.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer treatments using tumor-infiltrating lymphocytes (TILs). This is a cutting-edge and expensive technology. The chart shows the overall debt burden in the sector, giving investors insight into how Iovance finances its complex and lengthy clinical trials.
Debt to book value of all companies in the market
Iovance Biotherapeutics, Inc. is a biotechnology company developing innovative cancer treatments using T-cell therapy. This is a cutting-edge but very expensive technology. This chart shows that at the clinical development stage, Iovance can rely solely on equity capital, as debt financing is unavailable for such risky projects.
P/E of the company, segment and market as a whole
P/E - Iovance Biotherapeutics
This metric reflects high expectations for Iovance Biotherapeutics, a company developing cell therapy for cancer. The company has no profit, so a P/E ratio is not applicable. Its valuation reflects investors' faith that its innovative approach to cancer treatment will be successful and change the standard of care.
P/E of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotechnology company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of cancer. This chart shows the average valuation for the sector, helping to understand how the market views this innovative and personalized immuno-oncology platform.
P/E of the market as a whole
Iovance Biotherapeutics is a biotech company developing innovative cancer therapy based on tumor-infiltrating lymphocytes (TILs). Its valuation is a pure bet on the success of this complex and personalized technology. It is unrelated to the general economic cycles reflected in this chart. Its fate is decided in clinics and by regulators.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company developing innovative cell therapy for cancer (TIL-based therapy). Its valuation is based on the future success of this personalized approach. This chart reflects investors' belief in the breakthrough potential of this technology and its potential to become a new standard in the treatment of solid tumors.
%20P%2FE%20Iovance%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Iovance-Biotherapeutics&v=1772628423574 "Chart of the company's future (projected) P/E Iovance Biotherapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer therapies based on tumor-infiltrating lymphocytes (TILs). The chart reflects average expectations for the oncology segment. Iovance's position relative to this benchmark reflects investor assessments of the potential of their personalized approach to treating solid tumors such as melanoma.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772628423610 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Iovance Biotherapeutics is a biotech company developing innovative cancer treatments using T-cell therapy. Its value is based almost entirely on its future prospects. This graph of overall risk appetite shows how willing investors are to invest in science-intensive and risky projects with the potential to transform medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628423634 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company developing innovative cancer treatments using tumor-infiltrating lymphocyte (TIL)-based therapies. Its financial outlook is primarily driven by clinical trial expenses. Future profitability depends on the approval and commercial success of this complex therapy.
Profit of companies in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of innovative tumor-infiltrating lymphocyte (TIL)-based cancer immunotherapies. This chart shows the overall profitability of the immuno-oncology sector, reflecting investor willingness to fund cutting-edge cancer treatments.
Overall market profit
Iovance Biotherapeutics develops innovative cancer treatments using patient-derived immune cells (TIL therapies). This is a cutting-edge and risky area of biotechnology. The company's value depends on the success of clinical trials. However, the overall economic growth shown in this chart facilitates the significant investment needed to bring such a complex therapy to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company developing innovative cancer therapy based on tumor-infiltrating lymphocytes (TILs). Future revenue depends on the approval and commercial success of this complex cell therapy. This chart reflects analyst expectations regarding the potential of this cutting-edge technology for the treatment of solid tumors.
%20profit%20of%20the%20company%20Iovance%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Iovance-Biotherapeutics&v=1772628423735 "Graph of future (projected) profit of the company Iovance Biotherapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer therapy based on tumor-infiltrating lymphocytes (TILs). This method utilizes a patient's own immune cells to fight the disease. This chart shows forecasts for the biotech sector, helping to assess the potential of Iovance's breakthrough, yet risky, technology in oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772628423740 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Iovance Biotherapeutics develops innovative cell-based cancer treatments. The company's prospects are entirely dependent on clinical trial success and regulatory approval. General economic forecasts, such as those shown in this chart, do not have a significant impact on its operations.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628423758 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company developing innovative cancer therapy based on tumor-infiltrating lymphocytes (TILs). On the cusp of commercialization, it has a huge valuation with minimal revenue. This chart represents a pure bet by investors that its unique approach to cancer treatment will be a breakthrough.
P/S market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer immunotherapy using tumor-infiltrating lymphocytes (TILs). Future revenue depends on the success of this personalized approach. This oncology chart reflects investor expectations for Iovance's potential to offer new treatments for patients with solid tumors.
P/S of the market as a whole
Iovance Biotherapeutics is a clinical-stage biotech pioneering tumor-infiltrating lymphocyte (TIL) therapy for the treatment of solid tumors such as melanoma. This market revenue valuation chart helps illustrate the enormous value investors place on the potential of this personalized and innovative cell therapy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company pioneering the development of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors such as melanoma. This chart shows how the market is pricing in future sales of this innovative cell therapy, betting on its approval and commercial success.
%20P%2FS%20Iovance%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Iovance-Biotherapeutics&v=1772628423905 "The graph of the company's future (projected) P/S Iovance Biotherapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotechnology company pioneering the development of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors such as melanoma. The company's valuation reflects high expectations for its innovative approach to cancer cell therapy, which could be a breakthrough for many patients.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772628423978 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Iovance Biotherapeutics is developing tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of cancer. This is cutting-edge immuno-oncology. Revenue growth projections presented here do not take into account the paradigm-shifting potential of such revolutionary therapies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628423990 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company specializing in cancer cell therapy. This chart represents initial revenue from sales of its first commercial product, Amtagvi, intended for the treatment of melanoma. Growth will depend on the successful launch of the drug and its acceptance by physicians.
Sales of companies in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics (IOVA) is a biotech company pioneering the development of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors such as melanoma. This chart shows revenue in the immuno-oncology sector, where Iovance's innovative approach may offer new hope for patients with advanced cancer.
Overall market sales
Iovance Biotherapeutics is developing innovative cancer treatments using patient-derived immune cells (TIL-based therapies). Its success depends on the results of clinical trials. However, the overall economic situation, reflected in this chart, is affecting the willingness of healthcare systems and insurance companies to pay for cutting-edge, but very expensive, cell therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company developing innovative cancer treatments using tumor-infiltrating lymphocyte (TIL)-based therapies. Future revenue is dependent on the approval and commercialization of its cell therapy. This chart reflects analyst sales forecasts, which are a bet on the success of this cutting-edge approach in immuno-oncology.
%20sales%20of%20the%20company%20Iovance%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Iovance-Biotherapeutics&v=1772628424113 "Schedule of future (projected) sales of the company Iovance Biotherapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotech company developing innovative cancer therapies based on tumor-infiltrating lymphocytes (TILs). This graph shows the potential future revenue from their drugs after approval. This is an analyst's perspective on the commercial prospects of this personalized approach to cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772628424138 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Iovance Biotherapeutics is a late-stage biotech company specializing in the development of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of cancer. This chart, reflecting market sentiment, impacts the company's ability to raise capital for the commercial launch of its drugs after potential approval.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628424143 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company pioneering tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. While on the cusp of commercialization, the company incurs significant expenses. The chart shows the current profitability, which represents an investment in a potentially revolutionary cancer treatment.
Market segment marginality - Oncology immuno-therapy
Iovance Biotherapeutics is a biotechnology company pioneering the development of tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors such as melanoma. This chart depicts its path to profitability. Success is entirely dependent on the approval and commercialization of this innovative cell therapy.
Market marginality as a whole
Iovance Biotherapeutics is a biotech company developing innovative cancer therapies based on tumor-infiltrating lymphocytes. It is at the forefront of science and relies on investment. This total return chart reflects the market's willingness to fund complex and expensive developments. Economic optimism is driving capital flows into biotech.
Employees in the company, segment and market as a whole
Number of employees in the company Iovance Biotherapeutics
Iovance Biotherapeutics is a biotech company developing innovative cell therapies for cancer. As it nears commercialization, its team is growing significantly. This chart shows how the company is building manufacturing and commercial capacity to bring its complex product to market.
Share of the company's employees Iovance Biotherapeutics within the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is at the forefront of the fight against cancer, developing personalized cell therapy (TIL). This highly complex process requires a team of highly skilled scientists and cell manufacturing specialists. This graph reflects the enormous investment in human capital required to create "living therapies" for patients with solid tumors.
Number of employees in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics develops innovative cancer treatments using tumor-infiltrating lymphocyte (TIL)-based therapies. This chart, which shows employment in immuno-oncology, demonstrates how cutting-edge the field is. For Iovance, the growing number of specialists reflects both the recognition of cell therapy as a powerful weapon against cancer and competition for resources.
Number of employees in the market as a whole
Iovance Biotherapeutics is a clinical-stage company developing novel immunotherapies for cancer treatment. Their research advances drive the hiring of scientists and clinical experts. They are focused on medical innovation, seeking talent from a broader workforce to combat complex diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics is a biotechnology company developing innovative cancer therapy based on tumor-infiltrating lymphocytes (TILs). This approach is personalized medicine. This figure reflects the enormous value the market places on the potential of this complex and breakthrough technology, created by a team of highly skilled scientists.
%20of%20the%20company%20Iovance%20Biotherapeutics%20(IOVA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Iovance-Biotherapeutics-IOVA&v=1772628424335 "Chart of market capitalization per employee (in thousands of dollars) of the company Iovance Biotherapeutics (IOVA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is developing tumor-infiltrating lymphocyte (TIL)-based therapy for the treatment of cancer. This is a cutting-edge cell therapy. Its extremely high market capitalization reflects the market's high expectations that this technology will become a new standard of care for certain types of cancer.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772628424370 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Iovance Biotherapeutics is a biotechnology company developing innovative cancer treatments based on tumor-infiltrating lymphocyte (TIL) therapy. The chart reflects the valuation of its advanced scientific platform. The company's entire value is derived from its intellectual capital and the hope of approval of its treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628424461 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics is a biotech company pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer. They recently received approval for a drug. This graph will demonstrate how effectively their complex and customized manufacturing process and commercial team can generate revenue.
%20Chart%20Iovance%20Biotherapeutics%20(IOVA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Iovance-Biotherapeutics-IOVA&v=1772628424469 "Company Profit Per Employee (in thousands of dollars) Chart Iovance Biotherapeutics (IOVA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a biotechnology company pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer treatment. The company recently received FDA approval. This milestone represents the company's transition from focusing 100% of its R&D efforts to the commercialization of a highly complex and expensive cell therapy.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772628424479 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Iovance Biotherapeutics is a biotech company developing tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of cancer. This is a cutting-edge immuno-oncology company. The company is in the R&D stage and is not profitable. This chart is important to understand that in the cell therapy sector, employees (scientists) are the cost center, creating potentially revolutionary treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628424496 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics is a biotech pioneering tumor-infiltrating lymphocyte (TIL) therapy for cancer. Following the recent approval of its first product, revenue per employee has become a key metric for commercial launch. This chart will reflect the market penetration of this breakthrough cell therapy.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Iovance-Biotherapeutics-IOVA&v=1772628424515 "Sales chart per company employee Iovance Biotherapeutics (IOVA)")
Sales per employee in the market segment - Oncology immuno-therapy
Iovance Biotherapeutics (IOVA) is a biotech company specializing in cell-based cancer therapy (TIL therapy) using a patient's own immune cells. This chart shows the average revenue per employee in the segment. It helps assess how effectively Iovance is commercializing its complex therapies.
Sales per employee for the market as a whole
Iovance Biotherapeutics (IOVA) is a late-stage biotech company developing a tumor-infiltrating lymphocyte (TIL)-based therapy for the treatment of cancer. This is a complex cell therapy. The company is preparing for commercialization. This metric, which could soon change dramatically, will reflect how effectively they can manufacture and market this personalized treatment.
Short shares by company, segment and market as a whole
Shares shorted by company Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics (IOVA) is a biotech company pioneering tumor-infiltrating lymphocyte (TIL) therapy for the treatment of solid tumors such as melanoma. This chart shows "short" interest. High values may reflect investor concerns about the complexity and high cost of the TIL therapy manufacturing process, which could limit its commercialization. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Iovance-Biotherapeutics-IOVA&v=1772628424583 "Short Shares Chart for the Company Iovance Biotherapeutics (IOVA)")
Shares shorted by market segment - Oncology immuno-therapy
Iovance is a pioneer in TIL therapy, a cancer treatment that "educates" a patient's own T cells from a tumor. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech companies commercializing highly complex and expensive cell therapies.
Shares shorted by the overall market
Iovance Biotherapeutics (IOVA) is a biotech company working on cutting-edge cell therapy for cancer. They use a patient's own immune cells (TILs) to fight tumors. This is a very complex and expensive technology. This chart illustrates doubts about its commercial viability. Bears are betting that TIL production will be too complex and expensive for widespread use, or that trials will fail.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics is a pioneer in cancer treatment using TIL (tumor-infiltrating lymphocyte) therapy. This is a breakthrough but complex technology. This chart measures the roller coaster of hope. It shows when the stock is "overbought" on excitement about FDA approval or "oversold" on fears of production problems.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Iovance-Biotherapeutics-IOVA&v=1772628424688 "RSI 14 indicator chart for the company's stock Iovance Biotherapeutics (IOVA)")
RSI 14 Market Segment - Oncology immuno-therapy
Iovance Biotherapeutics is a pioneer in cell therapy, specializing in the treatment of solid tumors using tumor-infiltrating lymphocytes (TILs). Their drug, Amtagvi, is a breakthrough in melanoma treatment. This chart reflects the overall sentiment in the immuno-oncology sector, helping to assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Iovance Biotherapeutics (IOVA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IOVA (Iovance Biotherapeutics)
Iovance (IOVA) is a biotech company specializing in cell therapy (TIL) for the treatment of solid tumors, particularly melanoma. This chart shows the average target price, reflecting analysts' high confidence in the commercial success of its innovative cancer treatment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IOVA-Iovance-Biotherapeutics&v=1772628424741 "A chart showing analyst consensus forecasts for the expected stock price. IOVA (Iovance Biotherapeutics)")
The difference between the consensus estimate and the actual stock price IOVA (Iovance Biotherapeutics)
Iovance Biotherapeutics is a biotech company pioneering T-cell therapy (TIL) for the treatment of solid tumors, particularly melanoma. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current stock price and the consensus target price, demonstrating whether experts believe in this innovative therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IOVA-Iovance-Biotherapeutics&v=1772628424759 "A chart showing the difference between the consensus forecast and the actual stock price. IOVA (Iovance Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Iovance Biotherapeutics is a pioneer in TIL therapy. The company extracts immune cells (lymphocytes) from a patient's tumor, expands them, and reintroduces them to attack the cancer. This chart shows analysts' overall expectations for the entire immunotherapy sector. It reflects whether experts believe this complex cell therapy will be commercially successful.
Analysts' consensus forecast for the overall market share price
Iovance Biotherapeutics is a biotech company at the forefront of cancer cell therapy. They use tumor-infiltrating lymphocytes (TILs) to combat melanoma. This chart shows overall market sentiment. For Iovance, as an R&D company, how overall risk appetite (sentiment) influences funding for their breakthrough, but expensive, technology is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Iovance Biotherapeutics
Iovance (IOVA) is a biotech company at the forefront of oncology, developing tumor-infiltrating lymphocyte (TIL)-based therapies. This is a sophisticated, personalized cancer treatment. This chart represents an R&D bet. It reflects the market's confidence that their complex (but potentially breakthrough) cell therapy will receive FDA approval and become commercially successful.
AKIMA Market Segment Index - Oncology immuno-therapy
Iovance (IOVA) is a biotech pioneer in cancer immunotherapy; the company has developed revolutionary TILs (tumor-infiltrating lymphocytes) technology, a personalized treatment for melanoma. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does IOVA's breakthrough TILs R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Iovance Biotherapeutics is a pioneer in cell therapy (TIL) for the treatment of solid tumors. It received the first FDA approval for the treatment of melanoma (Amtagvi). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this story of commercializing breakthrough science compares to overall economic trends.
